Getting it right the first time: recent progress in optimizing antiemetic usage.

about

Getting it right the first time: recent progress in optimizing antiemetic usage.

Item

http://www.wikidata.org/entity/Q51738023

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Getting it right the first time: recent progress in optimizing antiemetic usage.

@en

Getting it right the first time: recent progress in optimizing antiemetic usage.

@nl

type

Item

label

Getting it right the first time: recent progress in optimizing antiemetic usage.

@en

Getting it right the first time: recent progress in optimizing antiemetic usage.

@nl

prefLabel

Getting it right the first time: recent progress in optimizing antiemetic usage.

@en

Getting it right the first time: recent progress in optimizing antiemetic usage.

@nl

P1476

Getting it right the first time: recent progress in optimizing antiemetic usage

@en

P2093

Lee Schwartzberg

http://www.w3.org/2001/XMLSchema#string

P2860

Prophylactic Management of Radiation-Induced Nausea and Vomiting

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomiz

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

P2888

s00520-018-4116-2

P304

19-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-018-4116-2

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lee S Schwartzberg

P577

2018-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29556812

http://www.w3.org/2001/XMLSchema#string

P932

5876255

http://www.w3.org/2001/XMLSchema#string